

Draft Minutes
Meeting of the Toxicology Subcommittee
of the Scientific Advisory Committee
Department of Forensic Science
October 5, 2026
All-Virtual Meeting

Subcommittee Members Present

Claire Dragovich
Marc A. LeBeau, PhD, *Chair*
Trey Miles

Staff Members Present

Kate Adolf, Western Latent Print & Impressions Section Supervisor, Acting Western Laboratory Director
David A. Barron, PhD, Deputy Director
James Hutchings, PhD, Toxicology Program Manager
Amy C. Jenkins, Chief Deputy Director
David Koppenhaver, Eastern Laboratory Director
Ryan Labor, Northern Controlled Substances Group Supervisor, Acting Northern Laboratory Director
Alka B. Lohmann, Director
David Siecker, Communications and Executive Support Specialist
Farryl Sorokin, Secretary to the Scientific Advisory Committee
Theresa Staropoli, Director of Technical Services
Rebecca Wagner, PhD, Chemistry Research Section Supervisor
William Wittenbrook, Department Counsel

Call to Order by Subcommittee Chair

After verifying that a quorum of the Toxicology Subcommittee ("Subcommittee") was present, Chair LeBeau called the meeting of the Subcommittee to order at 2:48 p.m. He reminded the members to speak clearly and to keep their cameras on throughout the meeting.

Adoption of Agenda

Chair LeBeau advised that the first order of business was the adoption of the draft agenda for the meeting and noted that the agenda was previously shared with the Subcommittee members by Ms. Sorokin. Chair LeBeau requested a modification to the draft agenda based on the Department's request to remove the review of one validation plan. Ms. Dragovich made a motion to adopt the amended agenda, which was seconded and passed by unanimous vote of the Subcommittee.

Adoption of Draft Minutes from the April 20, 2026 Subcommittee Meeting

Chair LeBeau noted that the draft minutes from the April 20, 2026 meeting of the Subcommittee were previously shared by Ms. Sorokin and asked if there were any proposed changes. Being none, Chair LeBeau asked for a motion to approve the minutes. Ms. Dragovich made a motion that the minutes be approved, which was seconded and adopted by unanimous vote.

Discussion of Validation Summary

47 In advance of the meeting, the members of the Subcommittee were provided with one validation
48 summary: *Utilization of a Circulating Bath in the Amphetamines, Phentermine, and Designer*
49 *Stimulants Quantitation and Confirmation by LCMSMS*. Dr. Wagner provided an overview of the
50 summary. Following her presentation, a question was raised seeking clarification about the
51 maximum time samples can be in the circulating bath. Additionally, a recommendation was made
52 to review and correct noted calculations.

53
54 After the discussion period, Chair LeBeau asked for a motion to close the review of *Utilization of*
55 *a Circulating Bath in the Amphetamines, Phentermine, and Designer Stimulants Quantitation and*
56 *Confirmation by LCMSMS Validation Summary* with the Department's review of calculations. Mr.
57 Miles made a motion to close the review pending the noted corrections, which was seconded and
58 passed by unanimous vote of the Subcommittee.

61 **Discussion of Validation Plans**

62 In advance of the meeting, the members of the Subcommittee were provided with three validation
63 plans: (1) *Addition of alpha-PVP-d8, Bupropion-d9, and MDPV-d8 to the Amphetamines,*
64 *Phentermine, and Designer Stimulants Quantitation and Confirmation by LCMSMS*, (2)
65 *Qualitative Basic Drug Screen by GC-MS* and (3) *Addition to the Miscellaneous Basic Drug*
66 *Quantitation and Confirmation by LCMSMS*.

67
68 Dr. Wagner provided an overview of the *Addition of alpha-PVP-d8, Bupropion-d9, and MDPV-*
69 *d8 to the Amphetamines, Phentermine, and Designer Stimulants Quantitation and Confirmation*
70 *by LCMSMS*. Following her presentation, a question was raised seeking clarification about the
71 lower limits of quantitation. Additionally, minor edits were addressed.

72
73 After the discussion period, Chair LeBeau asked for a motion to close the review of *Addition of*
74 *alpha-PVP-d8, Bupropion-d9, and MDPV-d8 to the Amphetamines, Phentermine, and Designer*
75 *Stimulants Quantitation and Confirmation by LCMSMS* subject to the modifications discussed.
76 Ms. Dragovich made a motion to close the review subject to the modifications discussed, which
77 was seconded and passed by unanimous vote of the Subcommittee.

78
79 Dr. Wagner provided an overview of *Qualitative Basic Drug Screen by GC-MS*. Following her
80 presentation, the Subcommittee discussed the limit of detection (LOD) values in biological
81 samples. Additionally, a request was made to add mass spectrometry acceptance criteria for a mass
82 match score of $\geq 80\%$.

83
84 After the discussion period, Chair LeBeau asked for a motion to close the review of *Qualitative*
85 *Basic Drug Screen by GC-MS* subject to the modifications discussed. Ms. Dragovich made a
86 motion to close the review, which was seconded and passed by unanimous vote of the
87 Subcommittee.

88
89 Dr. Wagner presented on the *Addition to the Miscellaneous Basic Drug Quantitation and*
90 *Confirmation by LCMSMS*. Following her presentation, a question was raised seeking clarification
91 regarding the evaluation of two internal standards for hydroxyzine. An additional minor edit was
92 recommended.

93
94 After the discussion period, Chair LeBeau asked for a motion to close the review of *Addition to*
95 *the Miscellaneous Basic Drug Quantitation and Confirmation by LCMSMS* subject to the
96 modifications and recommendations made. Ms. Dragovich made a motion to close the review,
97 which was seconded and passed by unanimous vote of the Subcommittee.
98

99 **Public Comment**

100 An opportunity for public comment was provided. No comments were made.
101

102 **Adjournment**

103 Chair LeBeau asked for a motion to adjourn the meeting. Mr. Miles made a motion to adjourn the
104 meeting, which was seconded and passed by unanimous vote of the Subcommittee. The meeting
105 adjourned at 3:27 p.m.